

## “Lack of population-specific genomic data is a significant challenge in the field of precision oncology”

31 January 2025 | Views | By Vrushti Kothari

Expanding its R&D capabilities to further enhance cancer detection and treatment efficacy, aligning with global efforts to revolutionise oncology care with the world observing World Cancer Day on February 4, Bengaluru-based startup 4baseCare has recently received a significant boost with Infosys investing Rs 8.3 crore to acquire a minority stake in the company. In conjunction with this, BioSpectrum took the opportunity to speak with Hitesh Goswami, Chief Executive Officer (CEO) and Co-Founder, 4baseCare regarding their future plans and advancements in precision oncology.



**With Infosys investing in 4baseCare, how do you plan to leverage this partnership to scale your operations, enhance technological capabilities, and drive growth?**

At 4baseCare, we drive innovation through two core solutions: Genomics and Digital Health. Our Genomics solutions focus on leveraging advanced genomic testing to identify actionable insights for personalised cancer care, while our Digital Health solutions encompass a comprehensive ecosystem designed to support patients and clinicians alike.

This includes everything from a patient-centric app that provides guidance throughout the cancer journey, to sophisticated tools that generate insights for predictive modeling, enabling personalised treatment strategies.

Collaborating with Infosys, a global leader in IT and digital transformation, we are enhancing the digital backbone of 4baseCare. Their expertise enables us to build a data-driven decision platform and develop pioneering solutions like the Clinico-Genomic Digital Twin (CG Twin)—a revolutionary model that integrates clinical and genomic data to create predictive insights for tailored cancer care. Together, we are bridging the gap between data, technology, and precision oncology to

empower patients and healthcare providers with innovative, impactful solutions.

**Besides this recent partnership, what were some of the other major developments at 4baseCare in 2024?**

The year 2024 has been a year of tremendous growth and significant milestones. We raised \$6 million in Series A funding led by Yali Capital, which enabled us to set up a genomics lab at Dubai Science Park in partnership with Innovate Life Sciences. We are also preparing to launch labs in the Philippines and Nepal.

We welcomed two industry leaders to our advisory board this year. Francis deSouza, former CEO of Illumina, and Lip-Bu Tan, Chairman of Walden International, to our advisory board. Their expertise in genomics and technology will play a critical role in our mission to make genomics accessible to all.

**Looking ahead to 2025, what are your key goals and initiatives, particularly in terms of expansion, partnerships, and impact on the precision oncology sector, in India and Asia?**

Collaborating with hospitals, research institutions, and pharmaceutical companies in Nepal, Bangladesh, and the Philippines remains central to our growth strategy. We aim to strengthen partnerships both in India and globally to bring advanced precision oncology solutions to patients.

In the next 1-2 years, we plan to launch educational initiatives such as workshops, webinars, and training programmes to support oncologists and clinicians in adopting genomic testing for cancer care. We also intend to expand our laboratory infrastructure, enhance bioinformatics platforms, and build a multidisciplinary team of experts in genomics, oncology, and data science. This will enable us to handle larger data and sample volumes while maintaining the highest standards of accuracy and quality.

With Series A funding from Yali Capital and Infosys Innovation Fund and the guidance of our esteemed advisors, we are well-positioned to expand our reach, drive innovation, and make precision oncology accessible to more cancer patients.

**Are you planning to launch new products/technologies in India or globally in 2025 or beyond? Please share details.**

Cancer is not a single disease- it is a collection of many diseases, each with its own unique complexities. Understanding cancer biology requires addressing the heterogeneity that makes it so intricate and challenging to treat.

At 4baseCare, we believe that a comprehensive and holistic approach is essential to truly unravel the molecular pathways of cancer. This means going beyond traditional core biopsies (solid biopsy) to include insights from cellular evolution by profiling circulating tumor DNA -ctDNA (liquid biopsy).

This innovative approach allows us to capture the dynamic nature of cancer, identifying genomic signatures that evolve over time and enabling precision care at every stage of the disease.

We recently launched our solution SoLiQ—our cutting-edge liquid biopsy technology that integrates genomic insights from both tissue and circulating tumour DNA, paving the way for more informed, personalised treatment strategies. With SoLiQ, we are redefining how cancer is understood and managed, ensuring no aspect of its complexity is overlooked.

**What are the current challenges facing the precision oncology market in India & neighbouring areas, and how are you addressing those?**

A significant challenge is the lack of population-specific genomic data. Much of the existing research and strategies are based on Western populations, which often fail to address the unique genomic diversity of Indian patients. Precision oncology in India is progressing but still lags behind Western nations.

Cancer is fundamentally a genomic disease making it essential to understand its molecular details to improve treatments and achieve better patient outcomes. Precision oncology, which integrates genomic biomarkers into the treatment paradigm, has rapidly emerged as a cornerstone of contemporary cancer care. However, the major challenge to Precision Oncology is that it is mostly based on genomics research and data on Caucasian population which puts our and other non-caucasian populations at a disadvantage. 4baseCare's vision is to bridge this data gap and push towards more evidence and data

backed treatment for cancer patients.

**What are your views on the growth of genomics startups in India? What does the future look like?**

Precision Oncology has seen steady adoption over the last decade and it is pretty clear that it is set to become a core part of cancer care in India over the next decade. Costs will decrease and more hospitals will adopt it. This change will be primarily driven by startups.

There will be easier access to targeted therapies and immunotherapies as more pharmaceutical companies enter the Indian market with cost-effective options. And with early detection becoming more common, we'll be able to identify high-risk individuals before cancer develops, shifting from treatment to prevention.

Technological advancements like artificial intelligence (AI) and big data integration will enhance genetic profiling, allowing oncologists to make faster and more precise decisions. With increased attention to clinical trials, India has the potential to emerge as a hub for precision oncology research.

***Vrushti Kothari***

***(vrushti.kothari@mmactiv.com)***